Activation of the ERK1/2 signaling pathway promotes phosphorylation and proteasome-dependent degradation of the BH3-only protein, Bim R Ley, K Balmanno, K Hadfield, C Weston, SJ Cook Journal of Biological Chemistry 278 (21), 18811-18816, 2003 | 779 | 2003 |
Tumour cell survival signalling by the ERK1/2 pathway K Balmanno, SJ Cook Cell Death & Differentiation 16 (3), 368-377, 2009 | 584 | 2009 |
Sustained MAP kinase activation is required for the expression of cyclin D1, p21Cip1 and a subset of AP-1 proteins in CCL39 cells K Balmanno, SJ Cook Oncogene 18 (20), 3085-3097, 1999 | 304 | 1999 |
Extracellular signal-regulated kinases 1/2 are serum-stimulated “BimEL kinases” that bind to the BH3-only protein BimEL causing its phosphorylation and turnover R Ley, KE Ewings, K Hadfield, E Howes, K Balmanno, SJ Cook Journal of Biological Chemistry 279 (10), 8837-8847, 2004 | 247 | 2004 |
Amplification of the driving oncogene, KRAS or BRAF, underpins acquired resistance to MEK1/2 inhibitors in colorectal cancer cells AS Little, K Balmanno, MJ Sale, S Newman, JR Dry, M Hampson, ... Science signaling 4 (166), ra17-ra17, 2011 | 246 | 2011 |
Activation of ERK1/2 by ΔRaf-1: ER* represses Bim expression independently of the JNK or PI3K pathways CR Weston, K Balmanno, C Chalmers, K Hadfield, SA Molton, R Ley, ... Oncogene 22 (9), 1281-1293, 2003 | 230 | 2003 |
ERK1/2‐dependent phosphorylation of BimEL promotes its rapid dissociation from Mcl‐1 and Bcl‐xL KE Ewings, K Hadfield‐Moorhouse, CM Wiggins, JA Wickenden, ... The EMBO journal 26 (12), 2856-2867, 2007 | 217 | 2007 |
Tumour cell responses to new fibroblast growth factor receptor tyrosine kinase inhibitors and identification of a gatekeeper mutation in FGFR3 as a mechanism of acquired resistance V Chell, K Balmanno, AS Little, M Wilson, S Andrews, L Blockley, ... Oncogene 32 (25), 3059-3070, 2013 | 177 | 2013 |
Intrinsic resistance to the MEK1/2 inhibitor AZD6244 (ARRY‐142886) is associated with weak ERK1/2 signalling and/or strong PI3K signalling in colorectal cancer cell lines K Balmanno, SD Chell, AS Gillings, S Hayat, SJ Cook International journal of cancer 125 (10), 2332-2341, 2009 | 168 | 2009 |
Carboplatin pharmacokinetics in children: the development of a pediatric dosing formula. The United Kingdom Children's Cancer Study Group. DR Newell, AD Pearson, K Balmanno, L Price, RA Wyllie, M Keir, ... Journal of clinical oncology 11 (12), 2314-2323, 1993 | 164 | 1993 |
RNA-binding proteins ZFP36L1 and ZFP36L2 promote cell quiescence A Galloway, A Saveliev, S Łukasiak, DJ Hodson, D Bolland, K Balmanno, ... Science 352 (6284), 453-459, 2016 | 151 | 2016 |
Apoptosis and autophagy: BIM as a mediator of tumour cell death in response to oncogene‐targeted therapeutics AS Gillings, K Balmanno, CM Wiggins, M Johnson, SJ Cook The FEBS journal 276 (21), 6050-6062, 2009 | 123 | 2009 |
ERK1/2 and p38 cooperate to induce a p21CIP1-dependent G1 cell cycle arrest DE Todd, RM Densham, SA Molton, K Balmanno, C Newson, CR Weston, ... Oncogene 23 (19), 3284-3295, 2004 | 117 | 2004 |
Adaptation to mTOR kinase inhibitors by amplification of eIF4E to maintain cap-dependent translation CL Cope, R Gilley, K Balmanno, MJ Sale, KD Howarth, M Hampson, ... Journal of cell science 127 (4), 788-800, 2014 | 95 | 2014 |
Colorectal cancer cells with the BRAFV600E mutation are addicted to the ERK1/2 pathway for growth factor-independent survival and repression of BIM JA Wickenden, H Jin, M Johnson, AS Gillings, C Newson, M Austin, ... Oncogene 27 (57), 7150-7161, 2008 | 95 | 2008 |
An mTORC1-to-CDK1 switch maintains autophagy suppression during mitosis RI Odle, SA Walker, D Oxley, AM Kidger, K Balmanno, R Gilley, ... Molecular cell 77 (2), 228-240. e7, 2020 | 85 | 2020 |
The duration of ERK1/2 activity determines the activation of c-Fos and Fra-1 and the composition and quantitative transcriptional output of AP-1 CJ Chalmers, R Gilley, HN March, K Balmanno, SJ Cook Cellular signalling 19 (4), 695-704, 2007 | 76 | 2007 |
ΔMEKK3: ER* activation induces a p38α/β2-dependent cell cycle arrest at the G2 checkpoint AP Garner, CR Weston, DE Todd, K Balmanno, SJ Cook Oncogene 21 (53), 8089-8104, 2002 | 68 | 2002 |
Thrombin inhibits Bim (Bcl-2-interacting mediator of cell death) expression and prevents serum-withdrawal-induced apoptosis via protease-activated receptor 1 CJ Chalmers, K Balmanno, K Hadfield, R Ley, SJ Cook Biochemical Journal 375 (1), 99-109, 2003 | 62 | 2003 |
Clinical pharmacokinetic and pharmacodynamic studies with the nonclassical antifolate thymidylate synthase inhibitor 3, 4-dihydro-2-amino-6-methyl-4-oxo-5-(4-pyridylthio … I Rafi, GA Taylor, JA Calvete, AV Boddy, K Balmanno, N Bailey, M Lind, ... Clinical cancer research: an official journal of the American Association …, 1995 | 55 | 1995 |